New HIV vaccine shows unprecedented success in preclinical study
A collaborative study between the La Jolla Institute for Immunology and Scripps Research has produced an HIV vaccine that successfully generates broadly neutralizing antibodies in primates. The vaccine works by training B cells to target vulnerable spots on the virus.
Why it matters
This represents a significant scientific breakthrough in the decades-long effort to develop an effective preventative vaccine for HIV/AIDS.
LA JOLLA, CA—A new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists, and IAVI has the potential to protect humans from developing HIV infection and AIDS. This HIV vaccine is the first to generate a high number of “broadly neutralizing,” virus-fighting antibodies in primates.
“This feels like a huge success,” says LJI Professor and Chief Scientific Officer Shane Crotty, Ph.D. , who co-led the research with Scripps Research Professor William Schief, Ph.D. “We constructed a successful vaccine from the ground up, which required a deep understanding of the immune system.”
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in